Key result
Different calcium channel blocker subtypes show no difference in 12-month eGFR or creatinine changes.
Why the study?
The longitudinal effects of different types of calcium channel blocker monotherapy on renal function in hypertensive diabetic patients were unclear.
Do different types of calcium channel blockers (L-, L/T-, L/N-, L/N/T-type) differentially affect renal function in hypertensive patients with diabetes mellitus?
Cohort (n=1,217)
Yes
Do different types of calcium channel blockers (L-, L/T-, L/N-, L/N/T-type) differentially affect renal function in hypertensive patients with diabetes mellitus?
Different types of calcium channel blockers used as monotherapy have similar, minimal effects on renal function in hypertensive patients with diabetes over 12 months.
Answers are grounded in this paper and cite their sources.
Similar renal effects across CCB subtypes in diabetic hypertension; hypothesis-generating and leaves randomized confirmation open.
BACKGROUND: We conducted a retrospective cohort study to evaluate and compare the longitudinal effect of monotherapy with L-, L/T-, L/N-, and L/N/T-type calcium channel blockers (CCBs) on estimated glomerular filtration rate (eGFR), and to investigate the association of treatment duration with eGFR in diabetic patients with hypertension. METHODS: Using a clinical database, we identified new users of five CCBs, i.e. amlodipine (L-type, n = 693), nifedipine (L-type, n = 189), azelnidipine (L/T-type, n = 91), benidipine (L/N/T-type, n = 183), and cilnidipine (L/N-type, n = 61). We used a multivariable regression model to evaluate and compare the effects of these drugs on eGFR and serum creatinine, up to 12 months after initiation of study drug administration. RESULTS: There was no significant association between treatment duration and both eGFR and serum creatinine level with all CCB types. In addition, there was no significant difference in mean change in eGFR among the five CCBs, with any treatment duration. CONCLUSIONS: Our findings suggest that monotherapy with an L-, L/T-, L/N/T-, or L/N-type CCB may have little influence on renal function parameters and may be safely used in hypertensive patients with diabetes.
No takes yet. Share an insight, caveat, or question.
Nishida et al. (2017) conducted a cohort in Diabetes mellitus with mild to moderate hypertension (n=1,217). Calcium channel blockers (amlodipine, nifedipine, azelnidipine, benidipine, cilnidipine) vs. Comparison among CCB types was evaluated on Change in estimated glomerular filtration rate (eGFR) (p=>0.05). Monotherapy with L-, L/T-, L/N/T-, or L/N-type calcium channel blockers showed no significant difference in the change in estimated glomerular filtration rate or serum creatinine over 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: